Skip to main content
. 2020 May 21;8(2):239. doi: 10.3390/vaccines8020239

Figure 3.

Figure 3

Detection of the HEV capsid protein and ds-RNA in HMOs and HMACs challenged with HEV inoculums (A) Representative gating strategy showing the expression of HEV ORF2 Ag in HMOs and HMACs infected with HEV. (left): HMOs infected with HEV-1. (Middle): HMACs infected with HEV-3, and (right): mock infected cells. Red histograms represent cells stained with the secondary A488 conjugated anti-mouse antibodies alone; blue histograms represent cells stained by mouse anti-HEV-ORF2 followed by A488-conjugated anti-mouse antibody. (B) Representatives showing HMOs (upper panel) or HMACs (lower panel) either uninfected (left side) or infected with HEV preparations (right side) were fixed and stained with anti-ds-RNA (J2 Ab) (red). DAPI was used for nuclear staining (blue) (Scale bars, 20 µm). Representative showing infection of HMOs with HEV-1 and infection of HMACs with HEV-3. (C) Supernatants collected from HEV-1 (solid line) and/or HEV-3 (dotted line)-infected HMOs (red) and HMACs (blue) were tested for HEV ORF2 Ag by ELISA, C.O is the cut off. Depicted are the mean values of three independent experiments  ± SEM.